Small Molecule

Small molecule chemistry remains the backbone of global pharmaceutical development. Despite the accelerated growth of biological modalities, small molecule drugs — which account for the large majority of medicines currently approved — continue to dominate the research and development portfolios of the pharmaceutical industry, biotechnology and academia. Their well-defined chemical synthesis, scalable manufacturing and structural diversity make them the foundation of a broad range of therapeutic programmes, from cardiovascular and oncological diseases to neurological disorders and infectious diseases.

The development of a small molecule drug requires specialised analytical support at every stage of the product lifecycle. In the R&D phase, bioanalysis, DMPK and biomarker services provide the exposure, metabolism and biological activity data that guide candidate selection, compound optimisation and decision-making in preclinical and clinical studies. In the quality control and CMC development domain, rigorous characterisation and control of the drug substance and the pharmaceutical product are non-negotiable requirements to ensure patient safety and achieve regulatory approval.

The analytical requirements of small molecule drugs are governed by a well-established regulatory framework encompassing ICH guidelines on impurities (ICH Q3A, ICH Q3B, ICH Q3C), stability (ICH Q1), method validation (ICH Q2(R2)) and bioanalysis (ICH M10), as well as the pharmacopoeial requirements of the Ph. Eur. and the USP. AMSbiopharma provides validated analytical services aligned with all of these regulatory frameworks, supporting small molecule programmes from early development stages through to quality control and commercial batch release.

From a quality framework perspective, services for small molecules span both regulated environments aligned with the principles of Good Laboratory Practice (GLP) — for preclinical studies and clinical bioanalysis — and Good Manufacturing Practice (GMP) environments — for CMC, quality control and batch release services — as well as non-regulated services for exploratory and research applications. To learn about the specific regulatory framework applicable to your project, we invite you to contact our team.

What are small molecule drugs?

Small molecule drugs are low molecular weight compounds — generally below 900 daltons — synthesised through defined chemical routes. This category encompasses an extraordinary structural diversity: from the simplest compounds to molecules of considerable synthetic complexity, including classically synthesised oral drugs, small synthetic peptides and small molecules produced by total chemical synthesis.

Their low molecular weight enables them, in many cases, to cross cell membranes, reach intracellular targets and even penetrate the blood-brain barrier, offering therapeutic advantages that biological modalities frequently cannot provide. Their production by chemical synthesis also offers advantages in terms of scalability, manufacturing cost and physicochemical stability, making them particularly attractive for the development of generic medicines and globally accessible, low-cost treatments.

Therapeutic application areas

Small molecule drugs are present across virtually all therapeutic areas. They underpin the most widely used treatments in oncology — including kinase inhibitors and alkylating agents — as well as in cardiology, neurology, infectious diseases and metabolic disorders. Growing interest in targeted therapy and precision medicine has further driven the development of new generations of highly specific small molecules, including covalent inhibitors, protein degraders (PROTACs) and allosteric activators.

Analytical challenges in small molecule development

The analytical development of small molecule drugs spans challenges ranging from the detection and quantification of process- and synthesis-related impurities at trace levels, to drug and metabolite quantification in complex biological matrices for DMPK and clinical bioanalysis studies, through to the rigorous control of related substances, residual solvents, nitrosamine impurities and extractables and leachables during quality control and batch release stages.

The need for highly sensitive, specific and reproducible analytical methods — validated in accordance with international regulatory standards — is a constant throughout the entire development lifecycle, from the first preclinical studies through to advanced clinical trials and commercial manufacturing.